1,061 reports of this reaction
3.2% of all LAPATINIB reports
#6 most reported adverse reaction
RASH is the #6 most commonly reported adverse reaction for LAPATINIB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,061 FDA adverse event reports linking LAPATINIB to RASH. This represents approximately 3.2% of all 32,865 adverse event reports for this drug.
Patients taking LAPATINIB who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is moderately reported among LAPATINIB users, representing a notable but not dominant share of adverse events.
In addition to rash, the following adverse reactions have been reported for LAPATINIB:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 1,061 FDA reports for LAPATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 3.2% of all adverse event reports for LAPATINIB, making it a notable side effect.
If you experience rash while taking LAPATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.